Calliditas Therapeutics AB (publ) (STO: CALTX)

Market Cap	11.24B
Revenue (ttm)	1.60B
Net Income (ttm)	-480.36M
Shares Out	54.03M
EPS (ttm)	-8.95
PE Ratio	n/a
Forward PE	16.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,081
Open	206.40
Previous Close	206.20
Day's Range	206.40 - 208.00
52-Week Range	80.80 - 208.80
Beta	1.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About CALTX

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 217
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CALTX

Financial Performance

In 2023, CALTX's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.